Cargando…

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands

PURPOSE: To compare treatment outcomes of treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD) with bevacizumab as the first‐line treatment, according to the guidelines of the Dutch Ophthalmological Society, with those treated first with either ranibizumab or aflibercept, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verbraak, Frank D., Ponsioen, Dirk L., Tigchelaar‐Besling, Odette A.M., Nguyen, Vuong, Gillies, Mark C., Barthelmes, Daniel, Klaver, Caroline C.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519105/ https://www.ncbi.nlm.nih.gov/pubmed/33354933 http://dx.doi.org/10.1111/aos.14712

Ejemplares similares

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021)

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration
por: Teo, Kelvin Y. C., et al.
Publicado: (2022)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
por: Onwuka, Oluchukwu, et al.
Publicado: (2023)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2022)

Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry
por: Riemer, Tommes, et al.
Publicado: (2023)

Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
por: Daien, Vincent, et al.
Publicado: (2021)

Correction to: Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry
por: Riemer, Tommes, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration
por: Ho, Allen C., et al.
Publicado: (2021)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
por: Zubricky, Ryan, et al.
Publicado: (2023)

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
por: Carrasco, Joao, et al.
Publicado: (2019)

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence
por: Wykoff, Charles C., et al.
Publicado: (2023)

Contextualizing single‐arm trials with real‐world data: An emulated target trial comparing therapies for neovascular age‐related macular degeneration
por: Thomas, Darren S., et al.
Publicado: (2021)

Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
por: Lai, Tso-Ting, et al.
Publicado: (2019)

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
por: Siempis, Thomas, et al.
Publicado: (2019)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu, Gahyung, et al.
Publicado: (2021)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema, Muhammad Raza, et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
por: Cho, Soo Chang, et al.
Publicado: (2023)

Impact of Loading Phase, Initial Response and CFH Genotype on the Long-Term Outcome of Treatment for Neovascular Age-Related Macular Degeneration
por: Menghini, Moreno, et al.
Publicado: (2012)

Treatment of age-related neovascular macular degeneration: the patient’s perspective
por: Müller, S., et al.
Publicado: (2017)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Association of neovascular age-related macular degeneration with migraine
por: Kuang, Tung-Mei, et al.
Publicado: (2022)

Levodopa Positively Affects Neovascular Age-Related Macular Degeneration
por: Figueroa, Anna G., et al.
Publicado: (2020)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u9m574t18rrolilk2aqc0hfi9o